InflaRx CSO reports holdings in Form 3
InflaRx N.V. director and Chief Scientific Officer Guo Renfeng filed an initial Form 3 showing his ownership in the company.
Rhea-AI Filing Summary
InflaRx N.V. director and Chief Scientific Officer Guo Renfeng filed an initial Form 3 showing his ownership in the company. He directly holds 1,762,144 Ordinary Shares and a series of stock options over additional Ordinary Shares with exercise prices ranging from 1.1700 to 2.4400, expiring between 2027 and 2036. Footnotes state that multiple option grants from 2016 through 2025 are already fully vested and exercisable, while a January 6, 2026 grant vests in four equal quarterly installments and a separate performance option depends on a financing event and the average Ordinary Share price in quarter four of 2026 exceeding $1.50.
Positive
- None.
Negative
- None.
Insider Trade Summary
13 transactions reported
Mixed
13 txns
Insider
Guo Renfeng
Role
Chief Scientific Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Performance Stock Option (Right to Buy) | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 3,816,197 contracts (Direct);
Performance Stock Option (Right to Buy) — 171,450 contracts (Direct);
Ordinary Shares — 1,762,144 shares (Direct)
Footnotes (12)
- F1. This option was granted on November 18, 2016 and is fully vested and exercisable as of the date hereof.
- F2. This option was granted on December 13, 2017 and is fully vested and exercisable as of the date hereof.
- F3. This option was granted on November 20, 2018 and is fully vested and exercisable as of the date hereof.
- F4. This option was granted on January 4, 2021 and is fully vested and exercisable as of the date hereof.
- F5. This option was granted on July 2, 2021 and is fully vested and exercisable as of the date hereof.
- F6. This option was granted on January 12, 2022 and is fully vested and exercisable as of the date hereof.
- F7. This option was granted on November 21, 2022 and is fully vested and exercisable as of the date hereof.
- F8. This option was granted on January 24, 2023 and is fully vested and exercisable as of the date hereof.
- F9. This option was granted on January 5, 2024 and is fully vested and exercisable as of the date hereof.
- F10. This option was granted on January 3, 2025 and is fully vested and exercisable as of the date hereof.
- F11. This option was granted on January 6, 2026 and will vest and become exercisable in four equal installments of 142,875 shares on each quarterly anniversary of such grant date, subject to continued service through such dates.
- F12. This option shall vest depending upon achievement of the following performance criteria: (i) 50% shall vest if a certain financing event takes place before the fourth quarter of 2026 and (ii) 50% shall vest if the average Ordinary Share price for quarter four of 2026 exceeds $1.50.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does Guo Renfeng report owning in InflaRx (IFRX) on this Form 3?
He reports direct ownership of 1,762,144 Ordinary Shares of InflaRx N.V. In addition, he holds multiple stock option grants over further Ordinary Shares with various exercise prices and expiration dates extending out to 2036.
What stock option grants does the InflaRx (IFRX) CSO hold?
He holds several Stock Option (Right to Buy) awards over Ordinary Shares, with exercise prices such as 1.8600, 2.4400, 2.3700, 1.7900, 2.4100 and 1.1700, each with distinct expiration dates from 2027 to 2036.
Which InflaRx (IFRX) options held by Guo Renfeng are already vested?
Footnotes explain that options granted on November 18, 2016, December 13, 2017, November 20, 2018, January 4, 2021, July 2, 2021, January 12, 2022, November 21, 2022, January 24, 2023, January 5, 2024 and January 3, 2025 are fully vested and exercisable.
How does the January 6, 2026 InflaRx (IFRX) option for Guo Renfeng vest?
The option granted on January 6, 2026 for 571,500 underlying Ordinary Shares will vest and become exercisable in four equal installments of 142,875 shares on each quarterly anniversary of that grant date, subject to continued service.
What are the performance conditions on the InflaRx (IFRX) performance stock option?
The performance stock option for 171,450 underlying Ordinary Shares vests in two halves: 50% if a specified financing event occurs before the fourth quarter of 2026, and 50% if the average Ordinary Share price for quarter four of 2026 exceeds $1.50.
AI-generated analysis. How Rhea-AI works. Not financial advice.
